Key result
QFR-guided PCI reduces 3-year MACE by ~45% in short lesions versus angiography guidance.
Why the study?
The clinical effect of QFR-guided PCI compared with angiography-guided PCI may be modified by coronary lesion length, which required investigation.
Does quantitative flow ratio (QFR)-guided PCI reduce major adverse cardiac events at 3 years compared to angiography-guided PCI in patients with short versus long coronary lesions?
RCT (n=3,825)
Double-blind (patients and outcome assessors)
1:1
Yes
Does quantitative flow ratio (QFR)-guided PCI reduce major adverse cardiac events at 3 years compared to angiography-guided PCI in patients with short versus long coronary lesions?
Hazard Ratio: 0.55 (95% CI 0.41–0.74)
Absolute Event Rate: 7.1% vs 12.6%
p-value: p=0.001
QFR-guided PCI significantly reduces the 3-year risk of major adverse cardiac events compared to standard angiography-guided PCI across varying coronary lesion lengths, with a particularly pronounced benefit in patients with shorter lesions.
QFR guidance may be prioritized for short lesions to reduce 3-year MACE; extends FAVOR III China by identifying lesion length as a potential effect modifier.
Background The FAVOR III China trial previously revealed that quantitative flow ratio (QFR)–guided percutaneous coronary intervention (PCI) achieved superior outcomes compared with angiography guidance. This predefined subgroup analysis was conducted to examine whether coronary lesion length modifying the clinical effect of QFR based revascularization strategy. Methods Overall, 3,825 patients were randomly assigned to either QFR-guided PCI (PCI performed only when QFR ≤ 0.80) or angiography-guided PCI. Lesions were categorized as long (≥ 20 mm) or short (< 20 mm), based on measurements from an independent imaging core laboratory. The primary study endpoint consisted of the composite of major adverse cardiac events (MACE), including myocardial infarction, ischemia-associated revascularization, and all-cause mortality over three years of follow-up. Results A total of 1,877 patients were classified into the long-lesion group (931 QFR-guided and 946 angiography-guided), and 1,925 into the short-lesion group (974 QFR-guided, 951 angiography-guided). After three years, patients with longer lesions had a greater incidence of MACE relative to those with shorter lesions (15.5% vs. 9.8%; P < 0.0001). Relative to angiography, QFR guidance led to a reduction in PCI procedures in both strata 14.8% in the short-lesion group and 2.4% in the long-lesion group. Relative risk reduction in MACE with QFR guidance was consistent regardless of lesion length: 7.1% versus 12.6% (HR = 0.55; 95% CI: 0.41–0.74) in the short-lesion group and 13.9% versus 17.0% (HR = 0.79; 95% CI: 0.63–1.00) in the long-lesion group (Pinteraction = 0.06). Conclusions QFR-guided PCI was linked to fewer MACE relative to PCI guided by angiography after three years. The relative benefit was most pronounced in patients with shorter lesions.
No takes yet. Share an insight, caveat, or question.
Jia et al. (2026) conducted an RCT in Coronary artery disease (n=3,825). Quantitative flow ratio (QFR)-guided PCI vs. Angiography-guided PCI was evaluated on Composite of major adverse cardiac events (MACE) at 3 years in patients with short lesions (< 20 mm) (HR 0.55, 95% CI 0.41-0.74, p=0.001). QFR-guided percutaneous coronary intervention reduced major adverse cardiac events over 3 years compared to angiography, with the relative benefit most pronounced in short lesions (HR 0.55).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: